Evidence map›Paper›PMID 31372243›Full record

ArticleCell death discovery2019

Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression

Tianli Shen, Zhengxi Chen, Ju Qiao, Xuejun Sun, Qian Xiao

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Tianli Shen *1Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi China.
Zhengxi Chen *2Department of Pharmacology, School of Medicine, Yale University, 10 Amistad St, New Haven, CT USA.
Ju Qiao4Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA USA.
Xuejun Sun1Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi China.
Qian Xiao2Department of Pharmacology, School of Medicine, Yale University, 10 Amistad St, New Haven, CT USA.
First Affiliated Hospital of Xi'an Jiaotong University · CNYale University · USNortheastern University · US

Funding

Cancer Immunotherapy: Mechanistic Insights to Improve Clinical BenefitR13CA236284 · NCI · KEYSTONE SYMPOSIA · PI JARVIS, THALE CROSS · 2019 to 2019
$18k
NCI NIH HHS R13 CA236284
6 · The paper itself

Abstract

Adenomatous polyposis coli (

Indexed as

Lung cancerTumour immunology

Identifiers

PMID31372243
PMCPMC6668384
OpenAlexW2964704127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.